Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver
Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ishii, Makoto [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms - Heyden, Mariano L.M. ELSEVIER, 2022, official journal of the European Federation for Pharmaceutical Sciences, New York, NY [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:51 ; year:2014 ; day:23 ; month:01 ; pages:180-188 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ejps.2013.09.017 |
|---|
| Katalog-ID: |
ELV034032002 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV034032002 | ||
| 003 | DE-627 | ||
| 005 | 20230625195658.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejps.2013.09.017 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014015000023.pica |
| 035 | |a (DE-627)ELV034032002 | ||
| 035 | |a (ELSEVIER)S0928-0987(13)00387-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 300 |a 330 |a 360 |q VZ |
| 084 | |a 85.05 |2 bkl | ||
| 084 | |a 85.06 |2 bkl | ||
| 084 | |a 89.52 |2 bkl | ||
| 100 | 1 | |a Ishii, Makoto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. | ||
| 520 | |a Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. | ||
| 650 | 7 | |a Imatinib |2 Elsevier | |
| 650 | 7 | |a Cytochrome P450 |2 Elsevier | |
| 650 | 7 | |a Gastrectomy |2 Elsevier | |
| 700 | 1 | |a Toda, Takahiro |4 oth | |
| 700 | 1 | |a Ikarashi, Nobutomo |4 oth | |
| 700 | 1 | |a Kusunoki, Yoshiki |4 oth | |
| 700 | 1 | |a Kon, Risako |4 oth | |
| 700 | 1 | |a Ochiai, Wataru |4 oth | |
| 700 | 1 | |a Machida, Yoshiaki |4 oth | |
| 700 | 1 | |a Sugiyama, Kiyoshi |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Heyden, Mariano L.M. ELSEVIER |t The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms |d 2022 |d official journal of the European Federation for Pharmaceutical Sciences |g New York, NY [u.a.] |w (DE-627)ELV009954198 |
| 773 | 1 | 8 | |g volume:51 |g year:2014 |g day:23 |g month:01 |g pages:180-188 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejps.2013.09.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 85.05 |j Betriebssoziologie |j Betriebspsychologie |q VZ |
| 936 | b | k | |a 85.06 |j Unternehmensführung |q VZ |
| 936 | b | k | |a 89.52 |j Politische Psychologie |j Politische Soziologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 51 |j 2014 |b 23 |c 0123 |h 180-188 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
m i mi |
|---|---|
| matchkey_str |
ishiimakototodatakahiroikarashinobutomok:2014----:oagsrcoyarslirdcdrgfetvnsdeonnraenhepesootergeaoi |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
85.05 85.06 89.52 |
| publishDate |
2014 |
| allfields |
10.1016/j.ejps.2013.09.017 doi GBVA2014015000023.pica (DE-627)ELV034032002 (ELSEVIER)S0928-0987(13)00387-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 300 330 360 VZ 85.05 bkl 85.06 bkl 89.52 bkl Ishii, Makoto verfasserin aut Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver 2014transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. Imatinib Elsevier Cytochrome P450 Elsevier Gastrectomy Elsevier Toda, Takahiro oth Ikarashi, Nobutomo oth Kusunoki, Yoshiki oth Kon, Risako oth Ochiai, Wataru oth Machida, Yoshiaki oth Sugiyama, Kiyoshi oth Enthalten in Elsevier Heyden, Mariano L.M. ELSEVIER The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms 2022 official journal of the European Federation for Pharmaceutical Sciences New York, NY [u.a.] (DE-627)ELV009954198 volume:51 year:2014 day:23 month:01 pages:180-188 extent:9 https://doi.org/10.1016/j.ejps.2013.09.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 85.05 Betriebssoziologie Betriebspsychologie VZ 85.06 Unternehmensführung VZ 89.52 Politische Psychologie Politische Soziologie VZ AR 51 2014 23 0123 180-188 9 045F 610 |
| spelling |
10.1016/j.ejps.2013.09.017 doi GBVA2014015000023.pica (DE-627)ELV034032002 (ELSEVIER)S0928-0987(13)00387-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 300 330 360 VZ 85.05 bkl 85.06 bkl 89.52 bkl Ishii, Makoto verfasserin aut Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver 2014transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. Imatinib Elsevier Cytochrome P450 Elsevier Gastrectomy Elsevier Toda, Takahiro oth Ikarashi, Nobutomo oth Kusunoki, Yoshiki oth Kon, Risako oth Ochiai, Wataru oth Machida, Yoshiaki oth Sugiyama, Kiyoshi oth Enthalten in Elsevier Heyden, Mariano L.M. ELSEVIER The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms 2022 official journal of the European Federation for Pharmaceutical Sciences New York, NY [u.a.] (DE-627)ELV009954198 volume:51 year:2014 day:23 month:01 pages:180-188 extent:9 https://doi.org/10.1016/j.ejps.2013.09.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 85.05 Betriebssoziologie Betriebspsychologie VZ 85.06 Unternehmensführung VZ 89.52 Politische Psychologie Politische Soziologie VZ AR 51 2014 23 0123 180-188 9 045F 610 |
| allfields_unstemmed |
10.1016/j.ejps.2013.09.017 doi GBVA2014015000023.pica (DE-627)ELV034032002 (ELSEVIER)S0928-0987(13)00387-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 300 330 360 VZ 85.05 bkl 85.06 bkl 89.52 bkl Ishii, Makoto verfasserin aut Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver 2014transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. Imatinib Elsevier Cytochrome P450 Elsevier Gastrectomy Elsevier Toda, Takahiro oth Ikarashi, Nobutomo oth Kusunoki, Yoshiki oth Kon, Risako oth Ochiai, Wataru oth Machida, Yoshiaki oth Sugiyama, Kiyoshi oth Enthalten in Elsevier Heyden, Mariano L.M. ELSEVIER The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms 2022 official journal of the European Federation for Pharmaceutical Sciences New York, NY [u.a.] (DE-627)ELV009954198 volume:51 year:2014 day:23 month:01 pages:180-188 extent:9 https://doi.org/10.1016/j.ejps.2013.09.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 85.05 Betriebssoziologie Betriebspsychologie VZ 85.06 Unternehmensführung VZ 89.52 Politische Psychologie Politische Soziologie VZ AR 51 2014 23 0123 180-188 9 045F 610 |
| allfieldsGer |
10.1016/j.ejps.2013.09.017 doi GBVA2014015000023.pica (DE-627)ELV034032002 (ELSEVIER)S0928-0987(13)00387-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 300 330 360 VZ 85.05 bkl 85.06 bkl 89.52 bkl Ishii, Makoto verfasserin aut Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver 2014transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. Imatinib Elsevier Cytochrome P450 Elsevier Gastrectomy Elsevier Toda, Takahiro oth Ikarashi, Nobutomo oth Kusunoki, Yoshiki oth Kon, Risako oth Ochiai, Wataru oth Machida, Yoshiaki oth Sugiyama, Kiyoshi oth Enthalten in Elsevier Heyden, Mariano L.M. ELSEVIER The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms 2022 official journal of the European Federation for Pharmaceutical Sciences New York, NY [u.a.] (DE-627)ELV009954198 volume:51 year:2014 day:23 month:01 pages:180-188 extent:9 https://doi.org/10.1016/j.ejps.2013.09.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 85.05 Betriebssoziologie Betriebspsychologie VZ 85.06 Unternehmensführung VZ 89.52 Politische Psychologie Politische Soziologie VZ AR 51 2014 23 0123 180-188 9 045F 610 |
| allfieldsSound |
10.1016/j.ejps.2013.09.017 doi GBVA2014015000023.pica (DE-627)ELV034032002 (ELSEVIER)S0928-0987(13)00387-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 300 330 360 VZ 85.05 bkl 85.06 bkl 89.52 bkl Ishii, Makoto verfasserin aut Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver 2014transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. Imatinib Elsevier Cytochrome P450 Elsevier Gastrectomy Elsevier Toda, Takahiro oth Ikarashi, Nobutomo oth Kusunoki, Yoshiki oth Kon, Risako oth Ochiai, Wataru oth Machida, Yoshiaki oth Sugiyama, Kiyoshi oth Enthalten in Elsevier Heyden, Mariano L.M. ELSEVIER The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms 2022 official journal of the European Federation for Pharmaceutical Sciences New York, NY [u.a.] (DE-627)ELV009954198 volume:51 year:2014 day:23 month:01 pages:180-188 extent:9 https://doi.org/10.1016/j.ejps.2013.09.017 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 85.05 Betriebssoziologie Betriebspsychologie VZ 85.06 Unternehmensführung VZ 89.52 Politische Psychologie Politische Soziologie VZ AR 51 2014 23 0123 180-188 9 045F 610 |
| language |
English |
| source |
Enthalten in The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms New York, NY [u.a.] volume:51 year:2014 day:23 month:01 pages:180-188 extent:9 |
| sourceStr |
Enthalten in The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms New York, NY [u.a.] volume:51 year:2014 day:23 month:01 pages:180-188 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Betriebssoziologie Betriebspsychologie Unternehmensführung Politische Psychologie Politische Soziologie |
| institution |
findex.gbv.de |
| topic_facet |
Imatinib Cytochrome P450 Gastrectomy |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms |
| authorswithroles_txt_mv |
Ishii, Makoto @@aut@@ Toda, Takahiro @@oth@@ Ikarashi, Nobutomo @@oth@@ Kusunoki, Yoshiki @@oth@@ Kon, Risako @@oth@@ Ochiai, Wataru @@oth@@ Machida, Yoshiaki @@oth@@ Sugiyama, Kiyoshi @@oth@@ |
| publishDateDaySort_date |
2014-01-23T00:00:00Z |
| hierarchy_top_id |
ELV009954198 |
| dewey-sort |
3610 |
| id |
ELV034032002 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV034032002</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625195658.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejps.2013.09.017</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014015000023.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV034032002</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0928-0987(13)00387-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">300</subfield><subfield code="a">330</subfield><subfield code="a">360</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.05</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.06</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">89.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ishii, Makoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Imatinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cytochrome P450</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gastrectomy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Toda, Takahiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ikarashi, Nobutomo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kusunoki, Yoshiki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kon, Risako</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ochiai, Wataru</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Machida, Yoshiaki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sugiyama, Kiyoshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Heyden, Mariano L.M. ELSEVIER</subfield><subfield code="t">The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms</subfield><subfield code="d">2022</subfield><subfield code="d">official journal of the European Federation for Pharmaceutical Sciences</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV009954198</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:51</subfield><subfield code="g">year:2014</subfield><subfield code="g">day:23</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:180-188</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejps.2013.09.017</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.05</subfield><subfield code="j">Betriebssoziologie</subfield><subfield code="j">Betriebspsychologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.06</subfield><subfield code="j">Unternehmensführung</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">89.52</subfield><subfield code="j">Politische Psychologie</subfield><subfield code="j">Politische Soziologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">51</subfield><subfield code="j">2014</subfield><subfield code="b">23</subfield><subfield code="c">0123</subfield><subfield code="h">180-188</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Ishii, Makoto |
| spellingShingle |
Ishii, Makoto ddc 610 ddc 300 bkl 85.05 bkl 85.06 bkl 89.52 Elsevier Imatinib Elsevier Cytochrome P450 Elsevier Gastrectomy Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver |
| authorStr |
Ishii, Makoto |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV009954198 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 300 - Social sciences 330 - Economics 360 - Social problems & services; associations |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 300 330 360 VZ 85.05 bkl 85.06 bkl 89.52 bkl Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver Imatinib Elsevier Cytochrome P450 Elsevier Gastrectomy Elsevier |
| topic |
ddc 610 ddc 300 bkl 85.05 bkl 85.06 bkl 89.52 Elsevier Imatinib Elsevier Cytochrome P450 Elsevier Gastrectomy |
| topic_unstemmed |
ddc 610 ddc 300 bkl 85.05 bkl 85.06 bkl 89.52 Elsevier Imatinib Elsevier Cytochrome P450 Elsevier Gastrectomy |
| topic_browse |
ddc 610 ddc 300 bkl 85.05 bkl 85.06 bkl 89.52 Elsevier Imatinib Elsevier Cytochrome P450 Elsevier Gastrectomy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
t t tt n i ni y k yk r k rk w o wo y m ym k s ks |
| hierarchy_parent_title |
The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms |
| hierarchy_parent_id |
ELV009954198 |
| dewey-tens |
610 - Medicine & health 300 - Social sciences, sociology & anthropology 330 - Economics 360 - Social problems & social services |
| hierarchy_top_title |
The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV009954198 |
| title |
Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver |
| ctrlnum |
(DE-627)ELV034032002 (ELSEVIER)S0928-0987(13)00387-4 |
| title_full |
Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver |
| author_sort |
Ishii, Makoto |
| journal |
The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms |
| journalStr |
The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
180 |
| author_browse |
Ishii, Makoto |
| container_volume |
51 |
| physical |
9 |
| class |
610 610 DE-600 300 330 360 VZ 85.05 bkl 85.06 bkl 89.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ishii, Makoto |
| doi_str_mv |
10.1016/j.ejps.2013.09.017 |
| dewey-full |
610 300 330 360 |
| title_sort |
total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme cytochrome p450, in the liver |
| title_auth |
Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver |
| abstract |
Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. |
| abstractGer |
Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. |
| abstract_unstemmed |
Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver |
| url |
https://doi.org/10.1016/j.ejps.2013.09.017 |
| remote_bool |
true |
| author2 |
Toda, Takahiro Ikarashi, Nobutomo Kusunoki, Yoshiki Kon, Risako Ochiai, Wataru Machida, Yoshiaki Sugiyama, Kiyoshi |
| author2Str |
Toda, Takahiro Ikarashi, Nobutomo Kusunoki, Yoshiki Kon, Risako Ochiai, Wataru Machida, Yoshiaki Sugiyama, Kiyoshi |
| ppnlink |
ELV009954198 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ejps.2013.09.017 |
| up_date |
2024-07-06T20:05:40.029Z |
| _version_ |
1803861455043297280 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV034032002</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625195658.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejps.2013.09.017</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014015000023.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV034032002</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0928-0987(13)00387-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">300</subfield><subfield code="a">330</subfield><subfield code="a">360</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.05</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.06</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">89.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ishii, Makoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract In patients with gastrectomy, it is possible that drug effectiveness is reduced compared to healthy subjects due to the increased of the drug-metabolizing enzyme, Cytochrome P450 (CYP). The purpose of this study is to verify this possibility. Gastrectomy model mice were prepared to evaluate the expression level of various CYPs in the liver from 2 to 24weeks post-operation. No significant differences were observed in the protein expression levels of CYP3A, CYP1A, CYP2C, and CYP2D between the sham operation group and the gastrectomy group up to 4weeks after the gastrectomy. On the other hand, significant increases in the protein expression levels of any CYPs were observed in the gastrectomy group compared to the sham operation group from 12weeks after the gastrectomy onward. These increases in expression levels were maintained until 24weeks after the gastrectomy. The examination of metabolic activity in the liver in the gastrectomy group using triazolam revealed that the metabolic activity at 12weeks after the gastrectomy was significantly increased in the gastrectomy group. The administration of the anticancer drug imatinib, which is a substrate of CYP3A, to mice at 12weeks after gastrectomy resulted in an increase in the metabolic rate, suggesting a possible decrease in drug effectiveness. It has been revealed that drug effectiveness may be reduced after gastrectomy because the expression levels of various CYPs in the liver were increased over a prolonged period. The results of this study can serve as valuable fundamental knowledge for drug therapy in patients with gastrectomy.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Imatinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cytochrome P450</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gastrectomy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Toda, Takahiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ikarashi, Nobutomo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kusunoki, Yoshiki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kon, Risako</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ochiai, Wataru</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Machida, Yoshiaki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sugiyama, Kiyoshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Heyden, Mariano L.M. ELSEVIER</subfield><subfield code="t">The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms</subfield><subfield code="d">2022</subfield><subfield code="d">official journal of the European Federation for Pharmaceutical Sciences</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV009954198</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:51</subfield><subfield code="g">year:2014</subfield><subfield code="g">day:23</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:180-188</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejps.2013.09.017</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.05</subfield><subfield code="j">Betriebssoziologie</subfield><subfield code="j">Betriebspsychologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.06</subfield><subfield code="j">Unternehmensführung</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">89.52</subfield><subfield code="j">Politische Psychologie</subfield><subfield code="j">Politische Soziologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">51</subfield><subfield code="j">2014</subfield><subfield code="b">23</subfield><subfield code="c">0123</subfield><subfield code="h">180-188</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.400483 |